Laptop Battery By Eric Stevenson
Negative studies flawed Until recently, the outcomes of clinical trials on glucosamine sulfate have been remarkably consistent. Many studies have shown that glucosamine sulfate, when taken for four to eight weeks at a dose of 500 mg three times daily, reduces the pain and stiffness associated with OA. blinded. Every clinical trial of glucosamine sulfate, save one, has found a beneficial effect on osteoarthritis, even when compared to standard treatments. Recently, several randomized, blind trials, have also shown a consistent therapeutic effect for chondroitin sulfate in the treatment of patients with OA.9 10
Thinkpad (AXcess News) San Francisco - Schering-Plough Corporation (NYSE: SGP), which holds a global monopoly on PEG-INTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) used in the treatment of chronic hepatitis C, sponsored a study in Canada that showed consistant results under real-life treatment of 952 patients across 160 clinics where doses of the drugs were given to patients based on weight. In the U.S. weight does not vary the amount of drugs prescribed.
- 4 found in the lizard' - helped people with type 2 diabetes shed pounds, year study found. The Gila monster is a venomous lizard that lives in the southwestern United States and northwestern Mexico. This study of 217 patients found that three years of treatment with the drug exenatide (brand name Byetta) resulted in sustained, progressive weight loss averaging 11 pounds. Many of the patients also showed sustained reductions in blood sugar levels and in blood biomarkers that indicate liver injury.
Microsoft Considering the pharmeceutical tactics Shering-Pough practices at U.S. clinics, where in many cases the drug company is literally officed within those facilities, AXcess News could not determine if that practice was conducted in Canada. Due to the drug manufacturers monopoly on the hepatitis C drug combination and the liver disease's deadly toll the Food and Drug Administration has not broached foreign generic manufacturing rights to the highly over-priced medication.
According to the indictment, Jones would steal various IBM and Penguin computer servers from Verisign's warehouse in Virginia and sell them to Johnson. Johnson would then sell the servers to several individuals, who would sometimes place them for sale on eBay. As a result of this scheme, the indictment alleges that Jones and Johnson caused Verisign to lose more than $120, 000 worth of computer equipment. In the indictment, Jones and Johnson are charged in three counts with causing the interstate transportation of stolen property, namely IBM 330 and 335 servers, in violation of 18 U.S.C.
Laptop Computers In the U.S., a patient prescribed by these Shering-Pough dominated medical clinics, or liver factories, pays $1,000 a month for the medication alone with no options for other, less expensive generic medications. Though in Canada, there may hope for some of the millions of people who suffer from this deadleast of diseases.
Mon, Dec 3, 2007 (HealthDay) — Annual weight checks, counseling about weight, stage treatment plan are among t...... More No link between hepatitis B shot and MS, study says Mon, Dec 3, 2007 (HealthDay News) — There's no link between vaccination to protect against hepatitis B and the risk of de...... More
Laptop Computer PEG-INTRON and REBETOL generate huge profits for Shering-Pough who defends their rates for the drug combination saying it cost them a lot to develop it. But that excuse runs thin as those without adequate or no medical insurance areunable to afford thecostly drugs. Shering-Pough, which does have a program for dispensing thedrugs tounderprivilegedsufferers of Hepatitis C do their best to not promote its existance - even going so far as coaching the liver clinics on dispensing the information sparingly.
In clinical studies of patients who have hepatitis B, 1 has been primarily investigated by itself, as the only therapy. However, 1 was used in combination with interferon or lamivudine. In addition, 1 has an excellent safety record. In the treatment of more than 3000 patients who had a range of diseases (including hepatitis B and hepatitis C), 1 was well tolerated and was not associated with any significant adverse effects.
Desktop Computer But the results of the Canadian study did show encouraging consistencies in arresting the disease's progress.
Notebooks The combination drug therapy achieved consistently high "Sustained Virological Response" (SVR) rates across all weight groups, with an overall SVR rate of 66 percent, the study showed. What that means is the virus did not multiply.
Lenovo The hepatitis C virus is so resiliant that even household bleach can't kill it. Today there are estimated to be 10 million people in the world who test positive for the disease and many do not even know they've contracted it. Hepatitis C has been diagnosed to be in three viral types, with Genotype 1 the most common - and the most deadly. The virus simply eats the liver until the liver is so badly damaged it can no longer function. It is the most common reason for liver transplants in the world.
Hard Drive Body weight has been shown in previous studies to affect SVR. In this study, patients were treated, followed and managed per standard of care in a "real-life" treatment setting with no study-related intervention beyond collection of data, Shering-Pough said.
Travelstar These results were reported for the first time at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Gateway In the study, PEG-INTRON (1.5 mcg/kg weekly) and REBETOL (800 - 1200 mg daily) combination therapy achieved SVR rates of greater than 62 percent in all weight groups (ranging from 62.9 percent to 68.9 percent), with no significant differences in SVR between the different weight groups, in 952 patients for whom SVR results have been collected to date. As expected, a higher percentage of patients with genotypes 2 or 3 achieved an SVR (85 percent and 78 percent, respectively) than patients with genotype 1 (52 percent). Genotype 1 is the most common form of the virus and is considered the most difficult to treat successfully.
Laptop Parts "These findings are particularly encouraging given that this is a 'real-life' community study with similar patient distribution by genotype within each weight group," said Paul Marotta, M.D., lead investigator, London (Ontario) Health Sciences Centre. "These results are consistent with the Canadian registration data for PEG-INTRON and REBETOL and underscore for patients the value of seeking treatment for hepatitis C, because the virus can be eradicated in a significant percentage of patients."
Software In the United States, PEG-INTRON (1.5 mcg/kg weekly) is approved in combination with REBETOL (800 mg daily) for a duration of treatment of 48 weeks. In the U.S. label, the SVR rate for this regimen is 52 percent. Weight-based dosing of REBETOL is currently under investigation in U.S. studies.
Hard Drives The study also revealed that 1% of the patients attempted or were successful at committing suicide either during or shortly after the treatment had ended.
Electronics In the U.S., in 2004 a 48-week treatment program would have cost $12,000 for the drugs alone. With 10 million estimated sufferers worldwide you can see why Shering-Pough will not give a license for the generic manufacture of the drugs and the Food and Drug Administration stands by, blind to the profits in excange for life tactics of this conciousless pharmaceutical company.
Canon But there is one alternative to PEG-INTRON, which is manufactured by Roche Holding AG (VTX: ROG). Pegasys, atreatment for hepatitis C that helps those patients to suppress the virus who have failed to benefit from rival Schering-Plough's Peg-Intron, Roche said.
Desktop Pc The Swiss drugmaker said on Friday that early results from a trial involving its Pegasys drug in combination with the antiviral ribavirin showed benefits in patients who had been unsuccessfully treated with Peg-Intron. Preliminary results from the trial showed that 47 percent of patients treated with the combination of Pegasys with ribavirin had undetectable amounts of the virus or a significant reduction in viral load after 12 weeks.
Desktop Computers The results were presented at the American Society for the Study of the Liver.
Think Pad Roche puts the number of people infected with hepatitis C at closer to 170 million worldwide.
Repair Pegasys and Peg-Intron, injectable long-acting forms of the immune system protein interferon, are both used in combination with antiviral pill ribavirin.
Data Recovery Drug makers are now looking at researching new medicines that can be used in a cocktail with existing treatments.
Cisco In early-stage Phase I data presented on Friday, Schering-Plough's SCH 503034 compound, a protease inhibitor, showed it had potent antiviral activity when combined with Peg-Intron.
Keyboard A similar drug by Vertex Pharmaceuticals Inc (Nasdaq: VRTX) is also moving to Phase II trials.
Monitor Idenix Pharmaceuticals Inc (Nasdaq: IDIX) said on Friday its drug NM283, in another class known as polymerase inhibitors, also worked well in combination with Pegasys. Novartis (VTX: NOVN) has an option to license in the pill.
[ Comment, Edit or Article Submission ]
